Resistance Is an Overflow Valve

01The evidence

• The lipid overflow-ectopic fat model accounts for insulin resistance as a consequence of fat arriving faster than adipose tissue can safely store it, with ectopic deposition in liver and muscle producing the resistance.Circulation
• Metabolic syndrome analyses in high-risk populations have invoked a failure of fat cell proliferation and fat oxidation as the upstream event, with resistance following rather than causing the lipid accumulation.Gulf metabolic syndrome

02The tension

Insulin resistance is treated as a signalling defect and a therapeutic target. Drugs that improve sensitivity are beneficial, which supports the framing, but the same drugs can worsen lipid storage and the benefit is not always durable. The ordering of causes is unresolved.

03The theory

Adipose tissue has a finite capacity to store lipid safely. When delivery exceeds that capacity, lipid accumulates in liver and muscle, where it interferes with insulin signalling. The resistance that follows reduces further glucose uptake and limits the lipid-driven damage.

On this account resistance is a valve, not a fault. It opens when overflow begins, and it closes when overflow stops. That predicts that resistance should be reversible by reducing lipid delivery even if receptor signalling is unchanged, and that it should precede hyperglycaemia because it is a response to the overflow rather than to the glucose.

The prediction is a temporal ordering: ectopic fat first, resistance second, glucose third. It also predicts that interventions which expand storage capacity, such as increasing adipocyte number, should improve sensitivity without touching the receptor.

The clinical consequence is that lipid delivery, not glucose, is the upstream target, and that resistance may be a marker of protection rather than a cause of harm in some patients.

04What this is not

05Predictions

• P1Ectopic lipid should precede insulin resistance, which should precede hyperglycaemia, in prospective cohorts.
• P2Reducing lipid delivery should restore sensitivity without changing receptor signalling.
• P3Expanding adipose storage capacity should improve sensitivity independently of receptor changes.

06What would refute it

Resistance appearing before any lipid overflow, in a prospective study, would restore the receptor-defect account.

07What it would change

It would redirect therapy toward storage capacity and lipid flux, and reframe resistance as a marker.